Recombinant DNA Advisory Committee - 09/9-10/93 
Haiping Wu, NHLBI 
Others: 
W. French Anderson, University of Southern California 
Bridget Binko, Cell Genesys, Inc. 
G'dali Braverman, Act Up 
Shannon Brownlee, U.S. News and World Report 
Rachel Carle, Genzyme Corporation 
Mike Casey, Genetic Therapy, Inc. 
Peter Cassileth, University of Miami School of Medicine 
Jan Chappell, Genetic Therapy, Inc. 
Fred Chang, University of Michigan 
Henry Chang, Shared Medical Research Foundation 
Yawen Chiang, Genetic Therapy, Inc. 
Edward Cohen, University of Illinois at Chicago 
Wanda deVlaminck, Avigen, Inc. 
Anne Driscoll, Cowen & Company 
Michelle Durand, The French Embassy 
James Economou, University of California, Los Angeles Medical Center 
Susan Falen, Genetic Therapy, Inc. 
Mitchell Finer, Cell Genesys, Inc. 
Diane Fleming, MID-Atlantic Biosafety Association 
Danielle Foullon, The Pink Sheet 
Joyce Frey, Food and Drug Administration 
Morgan Gale, National Narrowcast 
Richard Giles, MD Anderson Cancer Center 
Douglass Given, Progenitor, Inc. 
Phillip Greenberg, University of Washington 
David Holzman, BioWorld 
Thomas Horiagon, Chimerix, Inc. 
John Jaugstetter, Genentech, Inc. 
Susan Jenks, Journal of the National Cancer Institute 
Michael King, Alex Brown & Sons 
Toshihiko Komori, Chugai Pharma U.S.A., Inc. 
Steven Kradjian, Vical, Inc. 
John Krauss, University of Michigan Medical Center 
Larry Kun, St. Jude Children's Research Hospital 
Donald Longenecker, Viagene, Inc. 
Daniel Maneval, Canji, Inc. 
Gerard McGarrity, Genetic Therapy, Inc. 
Bruce Merchant, Viagene, Inc. 
Noel Messenger, Applied Immune Sciences, Inc. 
Robert Moen, Genetic Therapy, Inc. 
Elaine Morikawa, TV Asahi 
Arthur Nienhuis, St. Jude Children's Research Hospital 
[ 184 ] 
Recombinant DNA Research, Volume 18 
